Evidence map›Paper›PMID 40369416›Full record

ArticleBMC infectious diseases2025

In-depth analysis of the risk factors for persistent severe acute respiratory syndrome coronavirus 2 infection and construction of predictive models: an exploratory research study.

Jia Zhang, Weihua Zhu, Piping Jiang, Feng Ma, Yulin Li, Yuwei Cao, Jiaxin Li, Zhe Zhang, Xin Zhang, Wailong Zou and 1 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jia ZhangDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Weihua ZhuDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Piping JiangDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Feng MaDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Yulin LiDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Yuwei CaoDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Jiaxin LiDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Zhe ZhangDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Xin ZhangDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Wailong ZouDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China. 15301050459@163.com.
Jichao ChenDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China. 604939512@qq.com.

Funding

Beijing Association for Science and Technology Jinqiao Project for "Analysis of Clinical Characteristics and Risk Factors for Persistent SARS-CoV-2 Infection" SK20240040
6 · The paper itself

Abstract

backgroundPersistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection differs from long coronavirus disease (COVID-19) (acute symptoms ≥ 12 weeks post-clearance). The Omicron BA.5 variant has a shorter median clearance time (10-14 days) than the Delta variant, suggesting that the traditional 20-day diagnostic threshold may delay interventions in high-risk populations. This study integrated multi-threshold analysis (14/20/30 days), whole-genome sequencing, and machine learning to investigate diagnostic thresholds for persistent SARS-CoV-2 infection and developed a generalizable risk prediction model.

methodsThis retrospective study analyzed data from 1,216 patients with COVID-19 hospitalized at Aerospace Center Hospital between January 2021 and October 2024. We used whole-genome sequencing to genotype all COVID-19 cases and to identify major variants (such as Omicron BA. 5, Delta). The outcome, "persistent SARS-CoV-2 infection," was defined as viral nucleic acid positivity ≥ 14 days. Risk factors associated with persistent infection were identified through subgroup analysis with multiple logistic regression (adjusted for age, comorbidities, vaccination status, and virus strain) and machine learning models (70% training, 30% testing dataset).

resultsPersistent SARS-CoV-2 infection was identified in 15.5% (188/1,216) of hospitalized COVID-19 patients. Key predictors included comorbidities-hypertension, diabetes, and active malignancy-and immune dysfunction, marked by reduced B-cell and CD4 + T-cell counts. Unvaccinated patients exhibited an 82% higher risk of persistent infection. Elevated inflammatory markers (C-reactive protein and interleukin-6) and bilateral lung infiltrates on computed tomography further distinguished persistent cases. The predictive model demonstrated strong discrimination with an area under the curve (AUC) of 0.847 (95% confidence interval: 0.815-0.879) and an AUC of 0.81 externally in external validation, underscoring its clinical utility for risk stratification.

conclusionsHypertension, diabetes, malignancy, immunosuppression (low B/CD4 + cells), and non-vaccination are independent risk factors for persistent SARS-CoV-2 infection. Integrating these factors into clinical risk stratification may optimize management of high-risk populations.

Indexed as

COVID-19SARS-CoV-2AdultAgedFemaleHumansMachine LearningMaleMiddle AgedRetrospective StudiesRisk FactorsWhole Genome SequencingClinical manifestationsPersistent infectionPredictive model constructionRisk factorsSARS-CoV-2

Identifiers

PMID40369416
PMCPMC12080215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.